AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer's Disease
AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer's Disease
Jun 18, 2012
- New antibody program targets Tau protein, a major cause of Alzheimer's disease
- License agreement potentially worth more than Swiss Francs 400 Million (approximately USD 418 million*)
- Continuation of excellent long-term partnership based on development of crenezumab anti-Abeta antibody now in Phase II
- Goal to develop best-in-class and first-in-class antibodies for treatment and diagnosis of Alzheimer's disease